EN
SINOVAC Trivalent Influenza Vaccine Approved for Use From 6 Months of Age
BEIJING, October 30, 2025 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the National Medical Products Administration (NMPA) has approved a supplemental application for its trivalent influenza vaccine, Anflu® (0.5mL/dose), expanding its indication to include infants and young children aged 6 to 35 months. With this approval, the indication for Anflu® now covers all populations aged 6 months and older.
Launched in 2006, Anflu® was the first preservative-free trivalent influenza vaccine marketed in China. This latest age expansion follows the recent approval of SINOVAC's quadrivalent influenza vaccine (0.5mL/dose) for the same age group. This development aligns the dosage and administration of SINOVAC's seasonal influenza portfolio, providing robust immunization protection for the broader population, including highly vulnerable infants and young children of 6 to 35 months.
Beyond the mainland China market, SINOVAC's influenza vaccines have received regulatory approvals in other jurisdictions. In May 2025, both the trivalent and quadrivalent influenza vaccines were approved for registration in the Hong Kong Special Administrative Region, where they are currently the only domestically produced seasonal influenza vaccines approved for use. Internationally, SINOVAC influenza vaccines have been supplied to nearly 20 countries and regions. In Chile, SINOVAC supplied influenza vaccines for the country's publicly funded 2025 national immunization program, under which more than 7.8 million people had been vaccinated by October.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.